Coronavirus Disease 2019: Clinics, Treatment, and Prevention.
Coronavirus Disease 2019: Clinics, Treatment, and Prevention.
复制标题
DOI：
10.3389/fmicb.2021.761887
复制
发表时间：
2021
影响因子：
5.2
通讯作者：
Weiss G
中科院分区：
文献类型：
--
作者：
Burkert FR;Lanser L;Bellmann-Weiler R;Weiss G
2019 年冠状病毒病 (COVID-19) 大流行由一种新型严重急性呼吸综合征冠状病毒-2 (SARS-CoV-2) 引起，于 2019 年底在中国出现，通过感染及其健康后果，或由于卫生措施和遏制策略而对日常生活造成限制，影响了全世界人口。截至 2021 年 9 月，已报告超过 231,000,000 例因 COVID-19 感染和 4,740,000 例死亡。这些感染具有不同的临床症状和严重程度，从无症状病程到致命结果。已经确定了该疾病严重病程的几个危险因素，其中最重要的是年龄、性别、合并症、生活方式和遗传。虽然大多数患者会在几周内康复，但有些患者报告持续存在症状，限制了他们的日常生活和活动，这被称为“新冠肺炎后”。在过去的 18 个月里，我们获得了重要的知识，这反映在几乎无数的出版物上，涉及病毒的性质及其进化、宿主对感染的反应、传播方式以及疾病的不同临床表现。沿着这条线，新的诊断测试和算法已经开发出来，同时针对疾病的不同阶段寻找和临床评估特定的治疗方法。此外，还采取了预防性非药物措施来控制感染在社区的传播。虽然尚无有效的抗病毒疗法，但包括新型疫苗技术在内的多种疫苗已被开发出来，这些疫苗显示出对感染的高度保护，特别是对 COVID-19 引起的严重病程或死亡的保护。在这篇综述中，我们试图提供 COVID-19 的最新示意图，包括流行病学、病毒学、临床表现、诊断、治疗和预防等方面。
The coronavirus disease 2019 (COVID-19) pandemic, caused by a novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), emerged at the end of 2019 in China and affected the entire world population, either by infection and its health consequences, or by restrictions in daily life as a consequence of hygiene measures and containment strategies. As of September 2021, more than 231,000.000 infections and 4,740.000 deaths due to COVID-19 have been reported. The infections present with varied clinical symptoms and severity, ranging from asymptomatic course to fatal outcome. Several risk factors for a severe course of the disease have been identified, the most important being age, gender, comorbidities, lifestyle, and genetics. While most patients recover within several weeks, some report persistent symptoms restricting their daily lives and activities, termed as post-COVID. Over the past 18months, we have acquired significant knowledge as reflected by an almost uncountable number of publications on the nature of the underlying virus and its evolution, host responses to infection, modes of transmission, and different clinical presentations of the disease. Along this line, new diagnostic tests and algorithms have been developed paralleled by the search for and clinical evaluation of specific treatments for the different stages of the disease. In addition, preventive non-pharmacological measures have been implemented to control the spread of infection in the community. While an effective antiviral therapy is not yet available, numerous vaccines including novel vaccine technologies have been developed, which show high protection from infection and specifically from a severe course or death from COVID-19. In this review, we tried to provide an up-to-date schematic of COVID-19, including aspects of epidemiology, virology, clinical presentation, diagnostics, therapy, and prevention.
登录
查看更多内容
危及生命的Covid-19患者中针对I型IFN的自身抗体。
DOI：
10.1126/science.abd4585
发表时间：
2020-10-23
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Bastard P;Rosen LB;Zhang Q;Michailidis E;Hoffmann HH;Zhang Y;Dorgham K;Philippot Q;Rosain J;Béziat V;Manry J;Shaw E;Haljasmägi L;Peterson P;Lorenzo L;Bizien L;Trouillet-Assant S;Dobbs K;de Jesus AA;Belot A;Kallaste A;Catherinot E;Tandjaoui-Lambiotte Y;Le Pen J;Kerner G;Bigio B;Seeleuthner Y;Yang R;Bolze A;Spaan AN;Delmonte OM;Abers MS;Aiuti A;Casari G;Lampasona V;Piemonti L;Ciceri F;Bilguvar K;Lifton RP;Vasse M;Smadja DM;Migaud M;Hadjadj J;Terrier B;Duffy D;Quintana-Murci L;van de Beek D;Roussel L;Vinh DC;Tangye SG;Haerynck F;Dalmau D;Martinez-Picado J;Brodin P;Nussenzweig MC;Boisson-Dupuis S;Rodríguez-Gallego C;Vogt G;Mogensen TH;Oler AJ;Gu J;Burbelo PD;Cohen JI;Biondi A;Bettini LR;D'Angio M;Bonfanti P;Rossignol P;Mayaux J;Rieux-Laucat F;Husebye ES;Fusco F;Ursini MV;Imberti L;Sottini A;Paghera S;Quiros-Roldan E;Rossi C;Castagnoli R;Montagna D;Licari A;Marseglia GL;Duval X;Ghosn J;HGID Lab;NIAID-USUHS Immune Response to COVID Group;COVID Clinicians;COVID-STORM Clinicians;Imagine COVID Group;French COVID Cohort Study Group;Milieu Intérieur Consortium;CoV-Contact Cohort;Amsterdam UMC Covid-19 Biobank;COVID Human Genetic Effort;Tsang JS;Goldbach-Mansky R;Kisand K;Lionakis MS;Puel A;Zhang SY;Holland SM;Gorochov G;Jouanguy E;Rice CM;Cobat A;Notarangelo LD;Abel L;Su HC;Casanova JL
通讯作者：
Casanova JL
影响因子：
3.9
作者：
Bellmann-Weiler, Rosa;Lanser, Lukas;Weiss, Guenter
通讯作者：
Weiss, Guenter
DOI：
10.1016/j.mjafi.2020.08.004
发表时间：
2020-10-01
期刊：
Medical journal, Armed Forces India
影响因子：
--
作者：
Agrawal, Umang;Raju, Reyma;Udwadia, Zarir F
通讯作者：
Udwadia, Zarir F
影响因子：
56.3
作者：
Boehmer, Merle M.;Buchholz, Udo;Zapf, Andreas
通讯作者：
Zapf, Andreas
影响因子：
4.6
作者：
Banerjee, Arinjay;Subudhi, Sonu;Misra, Vikram
通讯作者：
Misra, Vikram